Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: Daw ?’-i-Dhay ?bi?us: Dose & Route of Administration: 2.5g Safuf (Powder) twice daily orally with water Duration of therapy:12 weeks
Control Intervention1: Tablet Metformin: Dose: 500mg
Sponsors
National Research Institute Of Unani Medicine for Skin Disorders
Eligibility
Inclusion criteria
Inclusion criteria: Fasting Blood Glucose (FBG) Levels between 126 and 150 mg/dL (after 8-12 hours of fasting) or Post-Prandial Blood Glucose (PPBG) Level between 200 and 250 mg/dL (after 2 hours of ingestion of meal) Glycated Haemoglobin (HbA1c) between 6.5% and 8% Patients willing to sign the written informed consent with / without Presence of any of the following symptoms of Dhay ?bi?us ? ?rr Qism Th ?ni (Type 2 Diabetes Mellitus): U?ash Mufri? (Polydipsia) Kathrat-i-Bawl (Polyuria) Kathrat-i-Ishtiha (Polyphagia) Bawl Layli (Nocturia) Burning sensation in palms and soles Naqs al-Wazn (Weight Loss) I’ya (Fatigue) D?u‘f-i-‘Am (General Weakness)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Fasting Blood Glucose (FBG), Post Prandial Blood Glucose (PPBG), HbA1c from baseline to post treatment at 12 weeksTimepoint: At baseline, 2, 4, 6, 8, 10 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in symptoms on VAS from baseline to post treatment at 12 weeksTimepoint: At baseline, 2, 4, 6, 8, 10 and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Saiyed Fatema Anjum
National Research Institute of Unani Medicine for Skin Disorders Hyderabad
Outcome results
None listed